Tag: Anticoagulants
Bleeding Higher With Standard-Dose DOACs in Nonvalvular A-Fib
Higher rate of bleeding seen with standard- versus reduced-dose DOACs in patients 65 years and older
Incident A-Fib Linked to Increased Risk of Mild Cognitive Impairment
Risk of MCI not increased for patients with incident a-fib receiving digoxin treatment or anticoagulant and amiodarone treatment
DOACs Reduce Dementia Risk Versus Warfarin in A-Fib
Significant reductions were seen in dementia risk for rivaroxaban, apixaban, and dabigatran versus warfarin in network meta-analysis
Apixaban Has Lower Bleeding Risk for Initial Anticoagulation for Venous Thromboembolism
During extended treatment, bleeding risk was similar for apixaban and rivaroxaban
Prolonged Direct Oral Anticoagulants Beneficial for Preventing Recurrent VTE
Findings seen among adults prescribed warfarin, DOACs beyond six months after acute venous thromboembolism
Ticagrelor-Acetylsalicylic Acid More Beneficial for Obese With Minor Stroke, TIA
Significantly lower rate of stroke within 90 days seen for ticagrelor-ASA versus clopidogrel-ASA for those carrying CYP2C19 loss-of-function allele
Anticoagulants Do Not Reduce Arterial Thrombotic Event Risk in Cancer
No reduction seen in risk of antithrombotic events but increased risk of major and minor bleeding
Benefits of Indefinite Anticoagulant Unclear After First VTE
Indefinite anticoagulation prevented recurrent VTE events, but induced major bleeding events
Catheter-Directed Thrombolysis Beneficial for Pulmonary Embolism
Systematic review showed risk for death and major bleeding complications was lower for catheter-directed thrombolysis than systemic thrombolysis
ASCO: Direct Oral Anticoagulant Therapy Feasible for Cancer Patients
Direct oral anticoagulants noninferior to low-molecular-weight heparin for venous thromboembolism prevention
